Moxifloxacin: Side Effects, Uses & Monitoring

1.1 Community Acquired Pneumonia Moxifloxacin hydrochloride tablets are indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including

Data source
FDA labeling via NIH DailyMed (label 6cbcf4d7…)
Label version
current
Last reviewed
2026
Side effects

Reported adverse reactions

Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.

Adverse reaction (as reported in labeling)Reported frequency*
Gastrointestinal disorders7%
Diarrhea6%
Nervous system disorders4%
Dizziness3%
Vomiting2%
Constipation2%
Abdominal pain2%
Psychiatric disorders2%
Blood and lymphatic system disorders1%
Dyspepsia1%
Investigations1%
Metabolism and nutritional disorder1%

*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.

Uses

Labeled uses (from FDA prescribing information)

1.1 Community Acquired Pneumonia Moxifloxacin hydrochloride tablets are indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see CLINICAL STUDIES (14.3)]. MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. 1.2 Uncomplicated Skin and Skin Structure Infections Moxifloxacin hydrochloride tablets are indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes [see CLINICAL STUDIES (14.4)]. 1.3 Complicated Skin and Skin Structure Infections Moxifloxacin hydrochloride tablets are indicated in adult patients for t…

Related conditions

Conditions associated with Moxifloxacin in labeling

FAQ

Frequently Asked Questions

What is Moxifloxacin used for?

FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.

What are the most commonly reported side effects of Moxifloxacin?

The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Moxifloxacin. Individual risk varies.

Does Moxifloxacin require lab monitoring?

Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Moxifloxacin.

Where does this information come from?

All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.

Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

Educational content only: The information on Symptom Database.com is for educational purposes and is not medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Read our full disclaimer.